Crescent Biopharma, Inc. (CBIO)
Crescent Biopharma, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Crescent Biopharma, Inc. (CBIO) is a Biotechnology company based in US with a market capitalization of $458.8M. Free cash flow was negative at -$72.5M. This page tracks CBIO's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 41 employees · IPO Jan 10, 2014
Valuation
Valuation & price
$19.97as of May 17, 2026· -26.0% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
2.26
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$458.8M
Market cap
—
Revenue growth (YoY)
100.0%
Gross margin
-$72.5M
Free cash flow (USD)
-$211.5M
Net debt
Net cash position
-46.6%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
1
Insider buys · 90 days
7
Insider sells · 90 days
Earnings
Last report: 10-Q/A filed Jun 22, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- Insider buyJul 20, 2026Filing
Insider Buy $12.4MFairmount Funds Management LLC · Director, 10% Owner · $12.4M
- 8-K eventJul 15, 2026Filing
Public Offering Announced
- 8-K eventJul 14, 2026Filing
Earnings Release
- FinancingJul 1, 2026Filing
Securities Registration
- Insider sellJun 23, 2026Filing
Insider Sell $761K · 10b5-1 PlanBrumm Joshua T · Director, Chief Executive Officer · $761.1K
- Insider sellJun 23, 2026Filing
Insider Sell $370K · 10b5-1 PlanMcNeill Jonathan · President and COO · $369.7K
- Insider sellJun 23, 2026Filing
Insider Sell $22K · 10b5-1 PlanIm Ellie Eunkyung · Chief Medical Officer · $21.9K
- Insider sellJun 23, 2026Filing
Insider Sell $22K · 10b5-1 PlanBispham Barbara Harlin · See Remarks · $21.9K
- Insider sellJun 23, 2026Filing
Insider Sell $20K · 10b5-1 PlanScalzo Richard William · Chief Financial Officer · $20K
- Insider sellJun 23, 2026Filing
Insider Sell $23K · 10b5-1 PlanPinkas Jan · Chief Scientific Officer · $23.2K
Questions
Frequently asked questions
What is Crescent Biopharma, Inc.'s market cap?
Crescent Biopharma, Inc. (CBIO) has a market capitalization of $458.8M.
What is CBIO's P/E ratio?
A meaningful P/E ratio is not available for CBIO — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is CBIO's price-to-book (P/B) ratio?
CBIO trades at 2.26 times book value per share.
Are insiders buying CBIO stock?
Yes — SEC Form 4 filings show 1 open-market insider buy and 7 sells at Crescent Biopharma, Inc. in the last 90 days.
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.